FDA Warns Drug Manufacturer Over Facebook Marketing Strategy
If you plan to mix Facebook and drug marketing, you need to make sure you know what you are doing. Or you could land in trouble with federal regulators, like pharmaceutical company Novartis.
The U.S. Food and Drug Administration has issued a warning to Novartis over the way it was marketing Tasigna, an anti-cancer drug. In a letter to Novartis sent on July 29, the FDA said the company’s use of Facebook Share was both incomplete and misleading.
An article in Bloomberg Business Week quotes the letter: “The shared content is misleading because it makes representations about the efficacy of Tasigna but fails to communicate any risk information associated with the use of this drug.
WORK SMARTER - LEARN, GROW AND BE INSPIRED.
Subscribe today!
To Read the Full Story Become an Adweek+ Subscriber
Already a member? Sign in